Abstract Library

#4088 Ex vivo expansion of TILs from panNET liver metastasis: In search of novel adoptive transfer strategies for the treatment of NETs

Introduction: It is unknown whether tumor infiltrating lymphocytes (TILs) from NETs may be an effective treatment in patients with NETs.

Conference:

Presenting Author: Chaoul N

Authors: Chaoul N, d'Angelo G, Giglio A, Mandriani B, Matrella M,

Keywords: panNET, TILs, adoptive T cell therapy, neoantigen-reactive TILs,

#4035 The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study

Introduction: Surufatinib (a small-molecule inhibitor of VEGFR1-3, FGFR1, and CSF-1R) has exhibited encouraging antitumor activity for the treatment of advanced neuroendocrine tumors (including NET and NEC) in multiple registration studies.

Conference:

Presenting Author: Jiang L

Authors: Jiang L, Chuntao W, Beiyuan H, Tao C, Haitao G,

Keywords: neuroendocrine tumor, real-world study, surufatinib,

#4029 An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms: MeTe study

Introduction: Metronomic schedule of temozolomide (mTEM) can overcome resistance induced by O6-methylguanine-DNA-methyltransferase (MGMT) and reduce toxicities being particularly suitable for unfit patients (pts). We present the first data from a non-planned interim analysis of this phase II Italian single arm multicenter study.

Conference:

Presenting Author: Spada F

Authors: Spada F, Jemos C, Pisa E, Bagnardi V, Frassoni S,

Keywords: Temozolomide, Metronomic, Chemotherapy, Frailty, MGMT, NEN, NET, QoL,

#4020 Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients

Introduction: Neuroendocrine tumors (NET) are malignant neoplasms that can be associated with specific hormonal syndromes.

Conference:

Presenting Author: Mulders M

Authors: Mulders M, Hofland J, de Herder W, van Velthuysen M, Roes E,

Keywords: ovary, neuroendocrine, tumor, estradiol, postmenopausal, bleeding,

#3949 Real-world study of Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) for high-grade neuroendocrine neoplasm

Introduction: Current therapeutic schedules of liver metastasis-dominated extrapulmonary high-grade neuroendocrine neoplasm (HG-NEN) have limited clinical benefits and liver metastasis progression is the main cause of death. Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor) showed promising antitumor activity in neuroendocrine neoplasm.

Conference:

Presenting Author:

Authors: Wang Y, Yu H, Yang D, Liu H, Yao W,

Keywords: Real-world study, surufatinib, hepatic artery infusion chemotherapy, high-grade neuroendocrine neoplasm,